Glenmark Pharmaceuticals has reached a settlement agreement with Pfizer, PF Prism CV, and PF Prism IMB BV (Pfizer) for Axitinib Tablets, 1 mg and 5 mg, the generic version of their Inlyta 1 Tablets, 1 mg and 5 mg. Glenmark had previously announced it received tentative approval by the United States Food & Drug Administration (US FDA) for their generic Axitinib Tablets, 1 mg and 5 mg on November 30, 2020.

According to IQVIA TM sales data for the 12 months ending September 2022, the Inlyta Tablets, 1 mg and 5 mg market 2 achieved annual sales of approximately $644.5 million.

Glenmark’s current portfolio consists of 177 products authorised for distribution in the US marketplace and 47 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.